Experimental group:pharmacological intervention

2 trials

Sponsors

Shenzhen People's Hospital, Yancheng First People's Hospital

Conditions

Esophageal squamous carcinomaModerate to severe chronic obstructive pulmonary disease (COPD)

Phase 3

A randomized, double-blinded, placebo-controlled phase III clinical trial, to evaluate the safety and efficacy of 611(Recombinant anti-IL-4Ra humanized monoclonal antibody) in Chinese adults with moderate to severe chronic obstructive pulmonary disease (COPD)

Active, not recruitingChiCTR2500104536

Shenzhen People's HospitalModerate to severe chronic obstructive pulmonary disease (COPD)

Start: 2025-07-15Updated: 2025-06-24

Phase 4

Prospective, Open-Label, Single-Center Clinical Study of QL1706 Combined Chemotherapy as Second-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

Active, not recruitingChiCTR2600123643

Yancheng First People's HospitalEsophageal squamous carcinoma

Start: 2026-05-01Updated: 2026-05-04